Replies to post #385268 on Innovation Pharmaceuticals Inc (IPIX)

[Here Today]

Nov 26 (Reuters) - Merck & Co (MRK.N) said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.

The drugmaker said its pill showed a 30% reduction in hospitalizations and deaths, based on data from 1,433 patients. In October, its data showed a roughly 50% efficacy, based on data from 775 patients. The drug, molnupiravir, was developed with partner Ridgeback Biotherapeutics.

[Here Today]

Seems like Merck was only “Pumping” their stats and left out all the bad stuff like deformities to unborn and other risk factors for certain individuals who might be adversely affected by taking Merck’s drug! If this gets approved, I lose complete faith in the FDA and where their heads are out because they simply said NO Go to Ridgeback when they owned the drug and now that Merck bought it, all of a sudden it’s good to go???? Stunning the hypocrisy and disgrace of how this system is being run in my opinion.